To read the full story, subscribe or sign in.

Novome gets $33M to back gut-focused chronic disease drive

Jan. 7, 2020

Novome Biotechnologies Inc., a startup developing a hyperoxaluria therapy based on controlled colonization of the gut with engineered bacteria, has landed a $33 million series A financing and appointed former Achaogen Inc. chief Blake Wise as CEO.

BioWorld Financings Newco news Endocrine/metabolic

Today's news in brief

BioWorld

BioWorld briefs for Sept. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 22, 2025.

The ‘molecular revolution’ driving R&D of new cancer therapeutics

BioWorld Asia

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...

Elderly woman holding illustration of brain with missing puzzle piece

Remynd’s REM-127 yields positive phase II data in Alzheimer’s

BioWorld

Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...

The domino effect of cutting mRNA vaccine research

BioWorld

In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing...